Strategic Innovation Area: SIO Chronic Diseases - SWElife
The first national structure for innovation support within life science in Sweden
In late May 2014, the innovation agency Vinnova decided to invest 100 million SEK in the development of the program SIO Chronic Diseases, wich has the overall aim to create better health and increased growth in Sweden. SIO Chronic Diseases includes a large number of actors from industry, health care, academia and innovation systems. SRP Diabetes has been actively involved in the development of the program which is one of five areas, and the only one in life science, that have been selected as a strategic innovation area with a national responsibility, “SIO.”
If Sweden is to remain competitive on the global life science stage, the opportunities for turning research results into innovations providing growth and benefit for patients need to be improved. SIO Chronic Diseases will take national responsibility for coordinating, managing, and developing sustainable innovation structures in order to enable Sweden to reach its full potential in the life science area.
The programme initially focussed on the diabetes area, in which generic innovation processes that can be applied to other therapy areas will be developed.
Since the autumn of 2012, SRP Diabetes has together with Lund University, Uppsala University, Karolinska Trial Alliance, Karolinska Innovations AB, Region Skåne and AstraZeneca developed an action plan with concrete initiatives that can facilitate and accelerate the development of new ways to prevent, diagnose, monitor, manage and treat diabetic patients. The focus has subsequently matured into an initiative that is appropriate for a SIO – SIO Chronic Diseases – focusing on chronic diseases, using diabetes as a pilot case. This was accomplished in collaboration with a similar strategic initiative aiming to develop a world-class ecosystem for life science in Sweden, coordinated by the County Administrative Board of Stockholm.
SIO Chronic Diseases, now baptized to SWElife, is chaired by Karolinska Institutet while the program office is located at Lund University which also has the coordinator role.
SWElife organizes a novel arena where academic researchers, industry, health care and private and public investors can meet.
SWElife DIABETES INNOVATION
Time: November 5, 2015
Place: Lustikulla Konferens & Event, Stockholm
IDENTIFY NEEDS – DISCUSS SOLUTIONS – FIND PARTNERS
This unique event is dedicated to fostering collaboration and innovation based on excellent research on diabetes, its risk factors and associated vascular complications. Connect with scientists in academia and industry, and the health care system, as well as with public and private investors in a highly interactive and informal environment.
Deadline for registration: 23 October
Calls for proposals
Latest call for proposals in the areas of prevention, diagnostics, therapy or devices within diabetes and other chronic diseases was made in spring 2015. See SWElife website for awarded projects.
The call for proposals offers funding for collaborative projects based on innovative and unique ideas informed by research or scientific knowledge that can be developed into strong new innovations in non-communicable diseases or their risk factors and complications.
The calls are targeted to consortia of higher education institutions, research institutes, healthcare organisations, companies and other relevant partners
SWElife Contact and information
Peter Nordström, coordinator
Read more about the development of SIO Chronic Diseases/SWElife
News at Lund University: http://www.ludc.med.lu.se/news-archive/100-millions-to-strengthen-the-swedish-life-science-sector/